For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Sales of Ethical Drugs Up 3.8% in November 2010
January 31, 2011
- NIBIO Reports Efficient Generation of Hepatoblasts from iPS Cells
January 31, 2011
- Korosho Withholds Approval of Norspan
January 31, 2011
- Top-Four Generics-Only Firms Expand Production Capacity
January 31, 2011
- PAFSC Committee Recommends Halaven for Approval
January 31, 2011
- TAIYO Pharm. Recalls Two Generics
January 31, 2011
- Dasen to Be Re-designated for Reevaluation
January 31, 2011
- Korosho to Consider Diabetes Treatment Strategy Using Incretin-Related Drugs
January 31, 2011
- Nichi-Iko to Transfer More Long-Listed Original Products to Nichi-Iko sanofi-aventis
January 31, 2011
- AZ Refuses Compromise Proposed by Courts over Iressa Lawsuits
January 31, 2011
- NICE Recommends Aricept for Mild AD as Well
January 31, 2011
- 70% of Women Would Like to Be Vaccinated against Cervical Cancer
January 31, 2011
- Kowa Applies for Peretinoin in Japan
January 31, 2011
- MSD to Propose Its Own Anti-Allergy Drugs Alone or in Combination for Pollinosis
January 31, 2011
- Yasuchika Hasegawa to Step Down as JPMA President, Isao Teshirogi to Succeed
January 31, 2011
- Korosho Cautions on the Use of Botulinum Toxin Types A, B
January 31, 2011
- Dialysis Costs Kyokaikenpo ¥175 Bil. Annually
January 31, 2011
- JPMA to Finalize GL for Disclosure of Funds Offered to Medical Institutions
January 31, 2011
- PMDA to Transfer GMP Compliance Inspection Power Earlier to Prefectures
January 31, 2011
- Sanofi-aventis Signs R&D Collaboration Agreements with UCSF
January 31, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…